Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16297265 | 1.00 | LMNA (0.48) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL3237311 | 1.00 | LMNA (0.48) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL5405861 | 0.83 | LMNA (0.41) | LMNAKDM4EL3MBTL1 | |
| SCHEMBL5405865 | 0.83 | LMNA (0.41) | LMNAKDM4EL3MBTL1 | |
| SCHEMBL7238090 | 0.83 | LMNA (0.41) | LMNAKDM4EL3MBTL1 | |
| SCHEMBL28144387 | 0.82 | LMNA (0.57) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL11829895 | 0.79 | AOC3 (0.48) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL7855317 | 0.79 | LMNA (0.54) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL2373419 | 0.79 | LMNA (0.48) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL7195212 | 0.79 | LMNA (0.53) | LMNAKDM4EL3MBTL1AOC3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031562-A1 | Method for Forming Allylic Alcohols | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2010025366-A2 | METHOD FOR FORMING ALLYLIC ALCOHOLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031562-A1 | Method for Forming Allylic Alcohols | ADH1A, ADH1C, ADH5 | LMNA 4303/4885KDM4E 3939/4885L3MBTL1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.